经痛愈舒对子宫内膜异位症大鼠NF-κB表达的防治作用
摘要
目的：
1采用自体移植法建立子宫内膜异位症(EMs)大鼠模型并动态观察其异位内膜病理学改变,确定经痛愈舒预防及治疗EMs的给药时间。
2观察经痛愈舒治疗性用药对EMs大鼠异位内膜组织病理学改变的影响,及其对NF-KB蛋白、RNA表达的干预效果,探讨经痛愈舒治疗EMs的可能机制,并为其临床应用提供实验依据。
3通过比较研究经痛愈舒预防性与治疗性用药干预EMs大鼠病理学表现及NF-KB蛋白、RNA表达的效果,探讨经痛愈舒预防性用药对EMs的影响及潜在作用机制。
方法：
1实验第一部分选用20只雌性未孕SD大鼠,随机分为5组；模型3天组、模型5天组、模型4周组、模型6周组及模型8周组,每组4只。均采用自体移植法建立EMs模型,各组分别于造模后第3天、第5天、第4周、第6周及第8周处死,苏木素伊红(HE)染色法观察异位内膜组织病理形态改变,并与正常SD大鼠子宫内膜对照
2实验第二部分选用造模成功的EMs大鼠72只,随机分为模型4周组、模型8周组,经痛愈舒低、中、高剂量组及西药组,每组12只,另取12只雌性未孕SD大鼠作为正常对照。各组大鼠分别予生理盐水或对应药物灌胃。其中模型4周组于造模4周后处死,其他各组均于造模后8周处死。HE染色观察各组大鼠异位内膜病理形态改变,免疫组.化法观察异位内膜NF-KB表达,Western blot法、RT-PCR法观察异位内膜NF-κB蛋白及RNA表达。
3实验第三部分选用36只EMs模型大鼠,随机分为模型组、经痛愈舒预防性用药组及经痛愈舒治疗性用药组,每组12只,另取12只雌性未孕SD大鼠作为正常对照。经痛愈舒预防性用药组于造模后5天给药,治疗性用药组于造模后5天予生理盐水,至造模后4周后再予经痛愈舒中药。各组大鼠均于造模后8周处死。HE染色观察各组大鼠异位内膜病理形态改变变化,免疫组化法、Westernblot法、RT-PCR法观察NF-κB表达。
结果：
1实验第一部分自体移植EMs大鼠模型造模成功率约70%。HE染色结果显示：与正常对照组比较,造模后3天异位内膜仅有少量炎性细胞侵润。造模后5天异位内膜间质结构松散、血供较差,尚未形成典型的内膜组织结构。造模后4周可观察到典型异位内膜组织形成。造模后6周及8周异位内膜病理表现与4周相似。
2实验第二部分异位内膜HE染色可见：经痛愈舒高剂量组及西药组内膜上皮细胞柱状增生,内膜间质松散,较多腺体萎缩,血供明显变差。
3免疫组化结果显示：模型4周组、8周组、经痛愈舒各组及西药组NF-κB表达明显高于正常对照组；经痛愈舒各组及西药组NF-κB表达明显低于模型8周组,且经痛愈舒高剂量组效果优于西药组。
4Western blot结果显示：模型4周组、8周组、经痛愈舒各组及西药组NF-κB蛋白表达明显高于正常对照组；经痛愈舒各组及西药组NF-κB蛋白表达明显低于模型8周组,且经痛愈舒中、高剂量组效果优于西药组。
5RT-PCR结果显示：模型4周组、模型8周组、经痛愈舒各组及西药组NF-κB RNA含量明显高于正常对照组；经痛愈舒各组及西药组NF-κB蛋白表达明显低于模型8周组,其中经痛愈舒中、高剂量组效果优于西药组。
6实验第三部分HE染色结果显示：经痛愈舒预防性及治疗性用药组内膜上皮萎缩变薄,间质细胞数量减少,异位内膜组织出现萎缩退变,其中预防性用药组改变更明显。
7免疫组化结果显示：模型组、经痛愈舒治疗组及预防组NF-κB表达明显高于正常对照组；经痛愈舒治疗组及预防组NF-κB表达明显低于模型组,但经痛愈舒治疗组及预防组NF-κB表达未见明显差异。8Western blot结果显示：模型组、经痛愈舒治疗组及预防组NF-κB表达明显高于正常对照组；经痛愈舒治疗组及预防组NF-κB表达明显明显低于模型组,但经痛愈舒治疗组及预防组NF-κB表达未见明显差异。
9RT-PCR结果显示：模型组、经痛愈舒治疗组及预防组NF-κB表达明显高于正常对照组；经痛愈舒治疗组及预防组NF-κB表达明显明显低于模型组,但经痛愈舒治疗组及预防组NF-κB表达未见明显差异。
结论：
1通过自体移植法可成功建立EMs大鼠模型,造模后5天可作为预防性用药干预时间点,造模后4周可作为治疗性用药干预时间点。
2经痛愈舒治疗性用药可在一定程度上促使EMs大鼠异位内膜组织萎缩退变,并抑制其NF-κB蛋白及RNA表达。
3经痛愈舒预防性用药亦可在一定程度上促进EMs大鼠异位内膜组织萎缩,并抑制其NF-κB表达,但与治疗性用药比较无明显差异。
Object i ve:
1To study the pathologic changes of the transplanted endometriotic tissues of the endometriosis rat model established by the method of autoplastic transplantation, to decide the best dosing time of prevention and therapy.
2To study the effect of "Jingtongyushu" on the pathologic changes as well as the protein and RNA expression of NF-κB in the transplanted endometriotic tissues of the endometriosis rat model, providing experimental foundation for using "Jingtongyushu" to remedy endometriosis.
3To study the effect of "Jingtongyushu" on the pathologic changes and the expression of NF-κB in the transplanted endometriotic tissues of the endometriosis rat model with preventive and therapy dosing separately, discussing the therapeutic mechanism of preventive dosing of "Jingtongyushu".
Methods:
1In the first part of animal research, female rat without offspring were divided into model3days group, model5days group, model4weeks group, model6weeks group and model8weeks group. There were4rats in each group. They were executed at3days,5days,4weeks,6weeks and8weeks after became endometriosis model established by the method of autoplastic transplantation. Then the pathologic changes of transplanted endometriotic tissues were compared with normal rats by the method of HE stain.
2In the second part of animal research,72endometriosis rats were divided into model4weeks group, model8weeks group,"Jingtongyushu" group (low-,medium-,high-dosage) and danazol group, using female rats without offspring as control group. There were12rats in each group. The4weeks group were executed after4weeks, other groups were executed after8weeks. The changes of transplanted endometriotic tissues, as well as the protein and RNA expressions of NF-κB were detected by HE stain, Immunohistochemical stain, Western blot and RT-PCR.
3In the third part of animal research,36endometriosis rats were divided into model group, preventive group and therapeutic group, using female rats without offspring as control group. There were12rats in each group. They were executed after8weeks, The changes of transplanted endometriotic tissues, as well as the protein and RNA expressions of NF-κB were detected by HE stain, Immunohistochemical stain, Western blot and RT-PCR.
Results:
1Endometriosis model were established satisfactorily by the method of autoplastic transplantation, the success rate was70percent. Model3days and model5days group didn't show mature transplanted endometriotic tissues, but model4weeks,6weeks and8weeks groups had already builds mature transplanted endometriotic tissues.
2"Jingtongyushu" high dosage group and danazol group effectively reduced the number of the endometrial stromal cells, and shrunk transplanted endometriotic tissues.
3The Immunohistochemical stain in first part showed that, compared with control group, NF-κB expression significantly increased in model groups,"Jingtongyushu" groups and danazol group. Compared with model8weeks group,"Jingtongyushu" high-dosage group and danazol group significantly decreased NF-κB expression, and "tongjingtong" high-dosage group had better effectiveness.
4The Western blot in first part showed that, compared with control group, the protein expression of NF-κB significantly increased in model groups,"Jingtongyushu" groups and danazol group. Compared with model8weeks group,"Jingtongyushu" high dosage group and danazol group significantly decreased protein expression, and "Jingtongyushu" medium,high-dosage groups had better effectiveness.
5The RT-PCR in first part showed that, compared with control group, the RNA expression of NF-κB significantly increased in model groups,"Jingtongyushu" groups and danazol group. The effect of "Jingtongyushu" and danazol groups was similar with the results of Western blot.
6In the third part of animal research,"Jingtongyushu" preventive and therapeutic groups had successfully shrink transplanted endometriotic tissues, the preventive group had better effectiveness.
7The Immunohistochemical stain in third part showed that, compared with control group, NF-κB expression significantly increased in model group, preventive and therapeutic groups. Compared with model group, preventive group and therapeutic group significantly decreased NF-κB expression, but there were no difference in these two groups.
8The Western blot showed that, compared with control group, the protein expression of NF-κB significantly increased in model group, preventive and therapeutic groups. Compared with model group, preventive group and therapeutic group significantly decreased the protein expression of NF-κB, but there were no difference in these two groups.
9The RT-PCR showed that, compared with control group, the RNA expression of NF-κB significantly increased in model group, preventive and therapeutic groups. The effect of preventive and therapeutic groups was similar with the results of Western blot.
Conclusion:
1Endometriosis model can be established successfully with the method of autoplastic transplantation. Choosing5days and4weeks after model built as the preventive, therapeutic dosing time.
2"Jingtongyushu" can shrink the transplanted endometriotic tissues of endometriosis model by decreasing its protein and RNA expressions of NF-κB.
3Preventive using of " Jingtongyushu" can also shrink the transplanted endometriotic tissues of endometriosis model, as well as decrease the protein and RNA expressions of NF-κB, but there was no difference between preventive and therapeutic groups.
1采用自体移植法建立子宫内膜异位症(EMs)大鼠模型并动态观察其异位内膜病理学改变,确定经痛愈舒预防及治疗EMs的给药时间。
2观察经痛愈舒治疗性用药对EMs大鼠异位内膜组织病理学改变的影响,及其对NF-KB蛋白、RNA表达的干预效果,探讨经痛愈舒治疗EMs的可能机制,并为其临床应用提供实验依据。
3通过比较研究经痛愈舒预防性与治疗性用药干预EMs大鼠病理学表现及NF-KB蛋白、RNA表达的效果,探讨经痛愈舒预防性用药对EMs的影响及潜在作用机制。
方法：
1实验第一部分选用20只雌性未孕SD大鼠,随机分为5组；模型3天组、模型5天组、模型4周组、模型6周组及模型8周组,每组4只。均采用自体移植法建立EMs模型,各组分别于造模后第3天、第5天、第4周、第6周及第8周处死,苏木素伊红(HE)染色法观察异位内膜组织病理形态改变,并与正常SD大鼠子宫内膜对照
2实验第二部分选用造模成功的EMs大鼠72只,随机分为模型4周组、模型8周组,经痛愈舒低、中、高剂量组及西药组,每组12只,另取12只雌性未孕SD大鼠作为正常对照。各组大鼠分别予生理盐水或对应药物灌胃。其中模型4周组于造模4周后处死,其他各组均于造模后8周处死。HE染色观察各组大鼠异位内膜病理形态改变,免疫组.化法观察异位内膜NF-KB表达,Western blot法、RT-PCR法观察异位内膜NF-κB蛋白及RNA表达。
3实验第三部分选用36只EMs模型大鼠,随机分为模型组、经痛愈舒预防性用药组及经痛愈舒治疗性用药组,每组12只,另取12只雌性未孕SD大鼠作为正常对照。经痛愈舒预防性用药组于造模后5天给药,治疗性用药组于造模后5天予生理盐水,至造模后4周后再予经痛愈舒中药。各组大鼠均于造模后8周处死。HE染色观察各组大鼠异位内膜病理形态改变变化,免疫组化法、Westernblot法、RT-PCR法观察NF-κB表达。
结果：
1实验第一部分自体移植EMs大鼠模型造模成功率约70%。HE染色结果显示：与正常对照组比较,造模后3天异位内膜仅有少量炎性细胞侵润。造模后5天异位内膜间质结构松散、血供较差,尚未形成典型的内膜组织结构。造模后4周可观察到典型异位内膜组织形成。造模后6周及8周异位内膜病理表现与4周相似。
2实验第二部分异位内膜HE染色可见：经痛愈舒高剂量组及西药组内膜上皮细胞柱状增生,内膜间质松散,较多腺体萎缩,血供明显变差。
3免疫组化结果显示：模型4周组、8周组、经痛愈舒各组及西药组NF-κB表达明显高于正常对照组；经痛愈舒各组及西药组NF-κB表达明显低于模型8周组,且经痛愈舒高剂量组效果优于西药组。
4Western blot结果显示：模型4周组、8周组、经痛愈舒各组及西药组NF-κB蛋白表达明显高于正常对照组；经痛愈舒各组及西药组NF-κB蛋白表达明显低于模型8周组,且经痛愈舒中、高剂量组效果优于西药组。
5RT-PCR结果显示：模型4周组、模型8周组、经痛愈舒各组及西药组NF-κB RNA含量明显高于正常对照组；经痛愈舒各组及西药组NF-κB蛋白表达明显低于模型8周组,其中经痛愈舒中、高剂量组效果优于西药组。
6实验第三部分HE染色结果显示：经痛愈舒预防性及治疗性用药组内膜上皮萎缩变薄,间质细胞数量减少,异位内膜组织出现萎缩退变,其中预防性用药组改变更明显。
7免疫组化结果显示：模型组、经痛愈舒治疗组及预防组NF-κB表达明显高于正常对照组；经痛愈舒治疗组及预防组NF-κB表达明显低于模型组,但经痛愈舒治疗组及预防组NF-κB表达未见明显差异。8Western blot结果显示：模型组、经痛愈舒治疗组及预防组NF-κB表达明显高于正常对照组；经痛愈舒治疗组及预防组NF-κB表达明显明显低于模型组,但经痛愈舒治疗组及预防组NF-κB表达未见明显差异。
9RT-PCR结果显示：模型组、经痛愈舒治疗组及预防组NF-κB表达明显高于正常对照组；经痛愈舒治疗组及预防组NF-κB表达明显明显低于模型组,但经痛愈舒治疗组及预防组NF-κB表达未见明显差异。
结论：
1通过自体移植法可成功建立EMs大鼠模型,造模后5天可作为预防性用药干预时间点,造模后4周可作为治疗性用药干预时间点。
2经痛愈舒治疗性用药可在一定程度上促使EMs大鼠异位内膜组织萎缩退变,并抑制其NF-κB蛋白及RNA表达。
3经痛愈舒预防性用药亦可在一定程度上促进EMs大鼠异位内膜组织萎缩,并抑制其NF-κB表达,但与治疗性用药比较无明显差异。
Object i ve:
1To study the pathologic changes of the transplanted endometriotic tissues of the endometriosis rat model established by the method of autoplastic transplantation, to decide the best dosing time of prevention and therapy.
2To study the effect of "Jingtongyushu" on the pathologic changes as well as the protein and RNA expression of NF-κB in the transplanted endometriotic tissues of the endometriosis rat model, providing experimental foundation for using "Jingtongyushu" to remedy endometriosis.
3To study the effect of "Jingtongyushu" on the pathologic changes and the expression of NF-κB in the transplanted endometriotic tissues of the endometriosis rat model with preventive and therapy dosing separately, discussing the therapeutic mechanism of preventive dosing of "Jingtongyushu".
Methods:
1In the first part of animal research, female rat without offspring were divided into model3days group, model5days group, model4weeks group, model6weeks group and model8weeks group. There were4rats in each group. They were executed at3days,5days,4weeks,6weeks and8weeks after became endometriosis model established by the method of autoplastic transplantation. Then the pathologic changes of transplanted endometriotic tissues were compared with normal rats by the method of HE stain.
2In the second part of animal research,72endometriosis rats were divided into model4weeks group, model8weeks group,"Jingtongyushu" group (low-,medium-,high-dosage) and danazol group, using female rats without offspring as control group. There were12rats in each group. The4weeks group were executed after4weeks, other groups were executed after8weeks. The changes of transplanted endometriotic tissues, as well as the protein and RNA expressions of NF-κB were detected by HE stain, Immunohistochemical stain, Western blot and RT-PCR.
3In the third part of animal research,36endometriosis rats were divided into model group, preventive group and therapeutic group, using female rats without offspring as control group. There were12rats in each group. They were executed after8weeks, The changes of transplanted endometriotic tissues, as well as the protein and RNA expressions of NF-κB were detected by HE stain, Immunohistochemical stain, Western blot and RT-PCR.
Results:
1Endometriosis model were established satisfactorily by the method of autoplastic transplantation, the success rate was70percent. Model3days and model5days group didn't show mature transplanted endometriotic tissues, but model4weeks,6weeks and8weeks groups had already builds mature transplanted endometriotic tissues.
2"Jingtongyushu" high dosage group and danazol group effectively reduced the number of the endometrial stromal cells, and shrunk transplanted endometriotic tissues.
3The Immunohistochemical stain in first part showed that, compared with control group, NF-κB expression significantly increased in model groups,"Jingtongyushu" groups and danazol group. Compared with model8weeks group,"Jingtongyushu" high-dosage group and danazol group significantly decreased NF-κB expression, and "tongjingtong" high-dosage group had better effectiveness.
4The Western blot in first part showed that, compared with control group, the protein expression of NF-κB significantly increased in model groups,"Jingtongyushu" groups and danazol group. Compared with model8weeks group,"Jingtongyushu" high dosage group and danazol group significantly decreased protein expression, and "Jingtongyushu" medium,high-dosage groups had better effectiveness.
5The RT-PCR in first part showed that, compared with control group, the RNA expression of NF-κB significantly increased in model groups,"Jingtongyushu" groups and danazol group. The effect of "Jingtongyushu" and danazol groups was similar with the results of Western blot.
6In the third part of animal research,"Jingtongyushu" preventive and therapeutic groups had successfully shrink transplanted endometriotic tissues, the preventive group had better effectiveness.
7The Immunohistochemical stain in third part showed that, compared with control group, NF-κB expression significantly increased in model group, preventive and therapeutic groups. Compared with model group, preventive group and therapeutic group significantly decreased NF-κB expression, but there were no difference in these two groups.
8The Western blot showed that, compared with control group, the protein expression of NF-κB significantly increased in model group, preventive and therapeutic groups. Compared with model group, preventive group and therapeutic group significantly decreased the protein expression of NF-κB, but there were no difference in these two groups.
9The RT-PCR showed that, compared with control group, the RNA expression of NF-κB significantly increased in model group, preventive and therapeutic groups. The effect of preventive and therapeutic groups was similar with the results of Western blot.
Conclusion:
1Endometriosis model can be established successfully with the method of autoplastic transplantation. Choosing5days and4weeks after model built as the preventive, therapeutic dosing time.
2"Jingtongyushu" can shrink the transplanted endometriotic tissues of endometriosis model by decreasing its protein and RNA expressions of NF-κB.
3Preventive using of " Jingtongyushu" can also shrink the transplanted endometriotic tissues of endometriosis model, as well as decrease the protein and RNA expressions of NF-κB, but there was no difference between preventive and therapeutic groups.
引文
[1]乐杰.妇产科学第七版[M].人民卫生出版社,325.
[2]Hassan HM.Incidence of endometriosis in diagnostic Laparoscopy J Repord Med 1976; 16(3) 135.
[3]Papavassiliou AG. Transcription factors.N Engl J Med,1995,332:45-47.
[4]Glass CK,Rose DW and Rosenfekd MG. Nuclear receptor co-activators. Current Opin Cell Biol,1997,9:222-232
[5]徐丛剑,金志军.子宫内膜异位症[M].北京：人民日报,2002,1.
[6]Mahmood TA, and Templeton A. Prevalence and genesis of endometri-osis [J]. Hum Reprod,1991,6:544.
[7]Nezhat CR, et al. Endometriosis.advanced management and surgical techniques[J]. Springer-Verlag New York,Inc.1995,3.
[8]连利娟.林巧稚妇科肿瘤学[M].北京：人民卫生出版社,2000年,715.
[9]江森.子宫内膜异位症研究的进展[J].中华妇产科杂志,1994,29(10)：624-626.
[10]高雪梅.腹腔镜检查诊断不明原因下腹痛的价值[J].实用妇产科杂志,2000,16(1)：39.
[11]丰有吉.妇产科学第七版[M].人民卫生出版社,356-357.
[12]Houston DES, Noller KL, Melton LJ 3rd,et al, Incidence of pelvic endometriosis in Rochester, Minnesota[J],1970-1979.Am J Epidemiol, 1987,126:959-969.
[13]Goldstein DP, DeCholnoky C, Emans SJ, et al. Laparoscopy in the diagnosis and management of pelvic Pain in adolescents[J]. J ReProd Med,1980,24:251-256.
[I4]Vessey MP,et al.Epidemiology of endometriosis in women attending family planning clinics[J]. BMJ,1993,306:182.
[15]周应芳.盆腔子宫内膜异位症发病因素的调查[J].中华妇产科杂志,1995,30(6)：356.
[16]潘凌亚.月经状况与子宫内膜异位症发病的关系[J].中华妇产科杂 志,1993,28：147.
[17]罗洁.203例子宫内膜异位症患者月经生殖状况分析[J].云南医药,2000,21(2)：125.
[18]张晓莉.106例子宫内膜异位症病因分析[J].实用医学杂志,1996,12(2)：95.
[19]CoPPeman AB and OliveD. Pathogenesis of pelvic pain in endomet-riosis. In Nezhat CR, et al.Endometriosis:advanced management and surgical techniques[J].NY.SPringer-Verlag,1995,37-43.
[20]Schulman H, et al. The uterine contractility index:a researcher and diagnostic tool in dysmenorrheal [J]. Am J Obstet Gynecol,1983,145:1049.
[21]Wild RA, Wilson EA. Clinical presentation and diagnosis in:Wilson EA Endometriosis[J]. NY. Alan R. Liss. Inc 1987,55-57.
[22]Dmowski WP. The role of medical management in the treatment of endometriosis [J], In:Nezhat CR, et al techniques.NY.Springer-Verlay.1995,229-240.
[23]许卫华,梁雪芳.月经与生殖状况与盆腔子宫内膜异位症关系的探讨[J].广州中医药大学学报,2002,19(1)：12
[24]Vessey MP.Vill ard-Mackintosh L,Painter R, Epidemiology of endometriosis in women attending family planning clinics [J]. BMJ, 1993,306:182-184.
[25]Sangi-Hagheyker H,Poindexter A 3rd.Epidemiology of endometrios is among parlous women[J]. Obstet Gynecol,1995,85 (6):983-992.
[26]王琳.子宫内膜异位症痛经患者腹腔液前列腺素测定28例分析[J].中国实用妇科与产科杂志,1996,12(2)：99.
[27]杨永斯.356例妇女子宫内膜异位症调查[J].广西医学,2002,24(4)：558.
[28]周应芳,王贞娟.子宫腺肌症患者妊娠和计划生育手术史调查[J].北京医学,1996,18(2)：78.
[29]周应芳.盆腔子宫内膜异位症和计划生育手术史的关[J]系.北京医学,1993.15：146.
[30]刘义.不孕妇女子宫内膜异位症发病因素的调查[J],同济医科大学学报,1997,26(1)：73-74.
[31]Makhlouf OC, et al. Endometriosis in lebanon:a Control study[J]. Am J Epidemiol,986;125:762
[32]潘凌亚.子宫内膜异位症发病与个体因素的关系[J].中华医学杂志,1995,75(1)：34.
[33]Parazzini F.Vercellini P.Panazza S,et al. Risk factors for adenomyosis. Hum Reproduce,1997,12:1275.
[34]Cramer DW, Wilson E, Stillman RJ et al. The relation of endometriosis to menstrual characteristics, smoking, andexercise-s.JAMA, 1986,255:1904.
[35]Signorello LB, et al. Epidemi ologic determinants of endometrio-sis: a hospital-based case-control study. Ann Epidemiol,1997,7(4):267.
[36]Berube S, et al. Characteristics related to the prevalence of minimal or mild endometriosis in infertilewomen. Canadian Collaborative Group onEndometriosis. Epidemiology,,1998,9(5):504.
[37]Grodstein F, Goldman MB, Ryan L et al.Relation of female infertility to consumption of caffeinated beverages.Am J Epidemiol,1993,137:1353.
[38]杨银芝译.子宫内膜异位症与机体脂肪分布有关.现代诊断与治疗,1994,5(3)：192.
[39]Signorello LB, et al. Epidemiologic determinates of endometr-iosis: a hospital-based case-control study. Ann E Epidemiol,1997,7(4): 267-741.
[40]Rier SE, Martin DC, Bowman RE, et al. Endometriosis in rhesus monkeys(Macaca mulatta)fol lowing chronic exposure to 2,3,78-tetrach lorodibenzo-P-dioxin. Fundam Appl Toxivol,1993,21(4):433.
[41]郭志荣,张琚,郎景和等.子宫腺肌症患者在位子宫内膜雌激素效应相关因子的时空变化[J].中华妇产科杂志,2004,39(4)：245.
[42]Dickinson CJ.Br J Obstet Gynaecol[M],1999:106:1003-1005.
[43]Hassan HM.Incidence of endometriosis in diagnostic Laparoscopy[J]. Repord Med 1976; 16(3) 135.
[44]纪巍,宋晖.子宫内膜异位症的发病机制研究[J].国外医学妇幼保健分册,2000,11(4)：145-147.
[45]Weed JC, Arquembourg PC. Endometriosis. Can it produce an autoimmune response resulting in infertility Obstet Gynecol[J], 1980,23:885.
[46]唐莉,黄荷凤.子宫内膜异位症的分子遗传学研究进展[J].国外医学妇产科学分册,2006,33(3)：177-283.
[47]Koninekx PR.Brosen IA.Reprod Med,1980,24:257-259.
[48]Kerr JF, Wyllie AH, Currie AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics [J].Br J Cancer.1972,26(4):239-257.
[49]Padykula HA.Regenratin of primate uterus:the role of stem cells.Ann NYA and Sci,2004,622:47-56.
[50]王立杰,郎景和.子宫内膜异位症疾病相关基因的研究[J].现代妇产科进展,2004,13(3)：190-193.
[5]Nisolle M,Casanas-Roux F, Donnez J. Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice. Fertil Steril.2000,74:306-312.
[52]Witz CA,Thomas MR,Montoya-Rodriguez ZA,et al. Short-term culture of peritoneum explants confirm attachment of endometrium to intact peritoneal me sothelium[J]. Fertil Steril.2001,75:385-390.
[53]Koks CA.M, Groothuis PG, Slaats P, Dunsilman GA.J, de Goeij AF.P, and Evers JL.H, Matrix metalloproteinases and their tissue inhibitors in antegradelyshed menstruum and peritoneal fluid[J]. Fertil Sterril, 2000,73:604-612.
[54]Folkman J:The role of angiogenesis in tumor growth [J].Semin Cancer Biol 1992;3:65-71.
[55]彭兆玉主编.子宫内膜异位症/妇产科专题讲座[M]。广东：广东科技出版社,1984,337-347.
[56]陈如钧,江鱼主编。不孕不育治疗学[M]。上海：上海科学技术出版社,1995,93-96.
[57]周应芳,子宫内膜异位症专家座谈会,中国实用妇科与产科杂志,2002,(3)：132.
[58]郎景和,冷金花等。子宫内膜异位症[J],现代妇产科进展,2006,15(3),165-166.
[59]石一复.子宫内膜异位的诊断与治疗现状[J].中华妇产科杂志,1996,31(10)：579-581.
[60]Kennedy S, Bergqvist A, ChaPron C, et al.ESHRE guideline for the diagnosis and treatment of endometriosis[J].Hum Reprod.2005,20: 2698-2704
[61]Aggarwal BB. Nuclear factor-kappa B:the enemy within[J]. Cancer Cell,2004,6:203-208.
[62]Shishodia S, Aggarwal BB. Nuclear factor-kappa B activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer[J].CancerTreat Res,2004,119:139-173.
[63]Grumont RJ, Gerondakis S.Rel induces interferon regulatory factor-4(IRF-4) expression in lymphocytes:modulation of interferon-regulated gene expression by Rel/nuclear factor kappa-B.Exp Med, 2000,1919(8):1281-1292.
[64]ChenF,Castranova V,Shi X, et al. New insights into the role of nuclear factor-kB, a ubiquitous transcription factor in the initiat ion of disease. Clin Chem,1999,45(1):7-17
[65]Raffi G, Raelene G, MathisG,et al. Rel/NF-Kb transcription factors:key mediators of B-cell activation. Immunol Rev,2000,176 (1):134-140.
[66]Neumann M, Naumann M. Beyond IJBs:alternative regulation of NF-kB activity[J].FASEB J Rev,2007,21:2642-2654.
[67]Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer:from innocent bystander to major culprit. Nat Rev,2002,Cancer 2:301-310
[68]Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammati on and cancer. Clin.In vest,2001,107:135-142.
[69]Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart:to be or not to NF-κB [J].Circ Res,2011,108 (9):1122-1132.
[70]Kawamura N, Kubota T, Kawano S, et al. Blockade of NF-κB improves cardiac function and survival without affecting inflamm-ation in TNF-A-induced cardiomyopathy [J]. Cardiovasc Res,2005,66:520-529.
[71]Brown M, Mc Guinness M, Wright T, etal. Cardiac-specific bloc-kade of NF-κB in cardiac pathophysiology:differences between acute and chronic stimuli in vivo[J]. Am J Physiol Heart Circ Physic,1 2005,289:H466-H476.
[72]De Martin R,Hoeth M, Hofe-Warbinek R,et al. The transcription factor NF-kappaB and the regulation of vascular cell fuction[J]. Arterioscler Thromb Vasc Biol 2000,20(11):83-88.
[73]Sasu S, Beasley D. Essential roles of I kappaB kinases alpha and beta in serum and IL-1-induced human VSMC proliferation[J].Am J Phsiol Heart Circ Physiol,2000,278(6):1823-1831.
[74]Chen Y, WU J. Ghosh G.KappaB-Ras binds to the unique insert within the ankyrin repeat domain of I kappaB beta and regulates cytoplasmic retention of I kappaB beta x NF-kappaB complexes[J]. J Biol Chem, 2003,278:23101-23106.
[75]Kanayama A, Seth RB, Sun L, et al.TAB2 and TAB3 Activate the NF-kappaB pathway through binding to polyubiqultin chains [J].Mol Cell,2004,15,535-548.
[76]Wong ET, Tergaonkar V. Roles of NF-kappa B in health and disease: mechanisms and therapeutic potential[J]. Clin Sci (Lond),2009,116(6) 451-465.
[77]Hayden MS, Ghosh S. Signaling to NF-κB [J]. Genes Dev,2004,18: 2195-2224.
[78]Yamamoto Y, Gaynor RB.IkappaB kinases:key regulators of the NF-kappaB pathway[J]. Trends Biochem Sci,2004,29:72-79.
[79]Hayden MS, Ghosh S. Signaling to NF-κB [J]. Genes Dev,2004,18: 2195-2224.
[80]Gilmore TD. Introduction to NF-κB:players, pathways, perspec-tives[J]. Onco-gene,2006,25:6680-6684.
[81]Janssens S, Tschopp J. Signals from within:the DNA-damage-induced NF-κB response[J].Cell Death Differ,2006,13:773-784 (review),21: 2642-2654
[82]Neumann M, Naumann M. Beyond I-κB s:alternative regulation of NF-κB activity [J].FASEB J Rev,2007,21:2642-2654.
[83]Lorenzo O,Picatoste B, Ares-C arrasco S, et al. Potential role of nuclear factor κB in diabetic cardiomyopathy[J].Mediators Inflamm,2011,2011: 652097.
[84]Perkins ND.Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway[J]. Oncogene,2006,25(51) 6717-6730.
[85]中国中西医结合学会妇产科专业委员会第三届学术会议.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准[S].中西医结合杂志,1991,11(6)：376.
[86]高月平.从痰论治子宫内膜异位症.山东中医杂志[J],2000,19(11)：693.
[87]吴凡,祖玉梅.辨证治疗子宫内膜异位症53例[J],辽宁中医杂志,1997,24(3)：122.
[88]马仲平等.韩冰教授辨证治疗子宫内膜异位症经验介绍[J].天津中医,1998,15(4)：230.
[89]吴新华等.康正消异颗粒对120例子宫内膜异位症患者免疫调节作用的影响[J].中医杂志,2003,44(9)：680.
[90]霍清萍.补肾化瘀法治疗子宫内膜异位症32例[J].江苏中医,1998,19(1)：24.
[91]贾美君.补肾疏肝化瘀法治疗子宫内膜异位症60例[J].新中医,2001,33(6)：53.
[92]周惠芳.补肾化瘀法治疗子宫内膜异位症34例[J].吉林中医药,1997,(5)：17.
[93]蔡辉.活血调经方治疗子宫内膜异位症的临床研究[J].中医药学报,199(1)：19.
[94]翟敏.穿蛭合剂治疗子宫内膜异位症48例临床观察[J].河北中医,1999,21(2)：87.
[95]王应兰等.温肾疏化法对子宫内膜异位症患者外周血TNF-α和IL-8的影响[J].山西中医,2002,18(4)：47.
[96]王砚琳.补肾疏肝、痰瘀同治法治疗子宫内膜异位症临床观察[J].山东中医杂志,2002,22(4)：207.
[97]陈建荣.中药综合治疗子宫内膜异位症50例临床观察[J].中国误诊学杂志,2002,2(3)：379.
[98]李友第,等.芪藤汤治疗复发性子宫内膜异位症48例[J].浙江中医杂志,2002：296.
[99]陆涛等.七厘失笑棱莪汤保留灌肠治疗子宫内膜异位症57例[J].上海中医药杂志,1998,(10)：38.
[100]倪建俐等.中药口服与灌肠治疗子宫内膜异位症的疗效对比观察[J].福建中医药,1999,30(4)：5.
[101]郑美华.当归芍药散加减治疗子宫内膜异位症体会[J].新疆中医药,2001,19(4)：19.
[102]吴根土.子宫内膜异位症、子宫腺肌病的中医证型与实时超影像图关系的分析[J].当代医学,2007,127(10)：87-88.
[103]薛江丽.分型论治子宫内膜异位症临床观察[J].山西中医,2013,29(9)：16.
[104]李鹤文.中西医治疗子宫内膜异位症的临床观察[J].四川中医,2013,31(8)：90-91.
[105]中华人民共和国卫生部.《中药新药临床研究指导原则》[M].北京：卫生部出版社,1993：263-265.
[106]赵富爱.辨证分型治疗子宫内膜异位症36例[J].山西中医,2008,24(3)：17-18.
[107]高耀洁,郭竞先.实用中西医结合妇产科学[M].第2版.郑州：河南科技出版社,2000：356.
[108]张丽蓉.求子必读·妇宝良方[M].天津：天津科技翻译出版社,1995：594.
[109]应瑛.化膜汤治疗子宫内膜异位症[J].浙江中医学院学报.1998,22(2)：23-24.
[110]朱振华.加味下瘀血汤治疗子宫内膜异位症42例[J].四川中医,2001,19(5)：49.
[111]钱静.温肾化瘀法治疗子宫内膜异位症的临床观察[J].南京中医药大学学报,2000,16(5)：277.
[112]司徒仪.莪棱胶囊治疗气滞血瘀型子宫内膜异位症临床研究,上海中医药杂志,2008,42(3)：46-48.
[113]蔡嘉兴.散结止痛汤治疗子宫内膜异位症临床研究[J]河北中医2000,2(：)8-9
[114]高琦,蔡霞.祛瘀散结方保留灌肠防治盆腔子宫内膜异位症术后复发疗效观察[J].新疆医科大学学报,2013,36(10)：1470-1472.
[115]周世谊.中药灌肠治疗子宫内膜异位症64例疗效观察[J].中国医药指南,2012,1 0(4)：226-228.
[116]赵月娥,程少华,叶林珍.中医外敷及灌肠治疗复发性子宫内膜移位症及控制内膜移位症复发的临床应用[J].齐齐哈尔医学院学报,2012,33(9)：1190.
[117]侯英慧,陈莹,中西医治疗子宫内膜异位症进展[J],辽宁中医杂志,2005,32(4)：377-378.
[118]张敏.腹舒粘敷贴治疗内脏平滑肌痉挛性疼痛临床疗效综述[J].今日科技,2006,6：44-45.
[119]夏红,江月华.中药敷贴治疗女性下腹痛333例[J].上海铁道大学学报(医学版),1996,10(3)：211-213.
[120]王倩,汪慧敏.麝香贴敷神阙穴治疗重度痛经的临床疗效观察[J].浙江中医学院学报,2004,28(4)：66.
[121]王金权等,女病外治良方妙法[M]第一版中国中医药出版社 1993：390-391.
[122]石燕华.针灸治疗子宫内膜异位症16例[J].上海针灸杂志,1995,14(4)：148-149.
[123]母丽杰,针灸治疗子宫内膜异位症72例疗效观察[J].中国当代医药,2012,19(12)：80-82)
[124]汪慧敏,侯钦銮.针灸治疗子宫内膜异位症46例[J].中医杂志,2001,42(6)：377-378.
[125]苏颖,张丽.治疗子宫内膜异位症经验[J].人泮中,2000,17(2)：2-3.
[126]陈建荣,等.中药综合治疗子宫内膜异位症50例临床观察[J].中国误诊学杂志,2002,2(3)：379.
[127]金季玲.内外合治子宫内膜异位症53例[J].南京中医药大学学报1999,15(6)：381.
[128]陈德甫,吴宁芬,狄文,子宫内膜异位症用雷公藤多试治疗[J],上海中医药杂志,1994,(9)：6.
[129]顾江红,何嘉琳等,雷公藤治疗子宫内膜异位症40例临床观察[J],中国中医药科技,2003,10(5)：301-302.
[130]赵君利,慕成莉.中西医结合治疗子宫内膜异位症痛经75例[J].福建中医药.2002.33(3)：11-12.
[131]朱文新.中西医结合治疗手术后复发内异症31例[J].中国中西医结合杂志.1997,(4)：241.
[132]解月波.中西医结合治疗子宫内膜异位症60例[J].湖南中医杂志.2003,19(2)：45.
[133]陈清郁.卵巢子宫内膜异位囊肿26例临床分析[J].贵阳医学院学报,2002,27(3)：3.
[l]Vernon MW, Wilson EA. Studies on the surgical induction of endometrio-sis in the rats. Fertile Sterile 1985,44(5):684-694.
[2]王群华,凌斌,赵卫东,等.人蜕膜移植建立NOD/SCID鼠子宫内膜异位症模型[J].安徽医科大学学报.2005,40(2)：99-101.
[3]Jones RC. The effect of a luteinizing hormone releasing hormone(LRH) agonist (Wy-40,972),levonorgestrel, danazol and ovariectomy on experimental endometriosis in the rat[J].Acta Endocrinol,1984, 106(2):282-288.
[4]周玲,钱志红,任琼珍.皮下注射子宫内膜法建立Lewis大鼠腹壁子宫内膜异位症模型[J].江苏医药,2012,38(13)：1513-1515.
[5]凌斌,王群华,陈峥峥,等.人免疫功能重建鼠子宫内膜异位症模型及建模方法[P]：[中国 安徽],200510037684.2005-08-03.
[6]Padykula HA.Regenratin of primate uterus:the role of stem cells.Ann NYA and Sci,2004,622:47-56.
[7]Keenan JA, Williams-Boyes PK, Massey PJ, et al. Regression of endometriosis explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril,1999, 72:135-139.
[8]郝光荣.实验动物学[J].上海：第二军医大学出版社,1999,177-178.
[9]Rajkumar K, Schott P W, Simpson C W, et al. The rat as an animal model for endometriosis to examine recurrence of ectopic endometrial tidue after regression. Fertil Steril,1990,53 (5):921.
[10]苗明三主编.实验动物和动物实验技术[M].北京：中国中医药出版社1997,323-324.
[11]杨耀芳,王钦茂,方学明,等.建立大鼠子宫内膜异位症模型的评价方法.中国药理学通报,1998,14(5)：469.
[12]常暖,韩冰,李同玺.大鼠子宫内膜异位症模型的建立及其病理学观察.临床与实验病理学杂志,1998,14：67-69.
[13]郑澄宇,杨冬梓,谢梅青,等.大鼠子宫内膜异位症模型的建立及其组织学观察.中山医科大学学报,2001,22：106-109.
[1]徐叔云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,2002.
[2]方肇勤.分子生物学技术在中医药研究中的应用[M]上海：上海科学技术出版社,2008.
[3]乐杰.妇产科学第七版[M].人民卫生出版社,325.
[4]Hassan HM.Incidence of endometriosis in diagnostic Laparoscopy J Repord Med 1976; 16(3) 135.
[5]Neumann M, Naumann M. Beyond IJBs:alternative regulation of NF-κB activity[J].FASEB J Rev,2007,21:2642-2654.
[6]Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer:from innocent bystander to major culprit. Nat Rev,2002,Cancer 2:301-310.
[7]Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. Clin.Invest.2001,107:135-142.
[8]Gonzalez-Ramos R, Dornnez J, Defrere S, et al.Nuclear factor-kappa B is constitutively activated in peritioneal endometriosis.Mol Hum Reprod,2007,13(7):503-509.
[2]Hassan HM.Incidence of endometriosis in diagnostic Laparoscopy J Repord Med 1976; 16(3) 135.
[3]Papavassiliou AG. Transcription factors.N Engl J Med,1995,332:45-47.
[4]Glass CK,Rose DW and Rosenfekd MG. Nuclear receptor co-activators. Current Opin Cell Biol,1997,9:222-232
[5]徐丛剑,金志军.子宫内膜异位症[M].北京：人民日报,2002,1.
[6]Mahmood TA, and Templeton A. Prevalence and genesis of endometri-osis [J]. Hum Reprod,1991,6:544.
[7]Nezhat CR, et al. Endometriosis.advanced management and surgical techniques[J]. Springer-Verlag New York,Inc.1995,3.
[8]连利娟.林巧稚妇科肿瘤学[M].北京：人民卫生出版社,2000年,715.
[9]江森.子宫内膜异位症研究的进展[J].中华妇产科杂志,1994,29(10)：624-626.
[10]高雪梅.腹腔镜检查诊断不明原因下腹痛的价值[J].实用妇产科杂志,2000,16(1)：39.
[11]丰有吉.妇产科学第七版[M].人民卫生出版社,356-357.
[12]Houston DES, Noller KL, Melton LJ 3rd,et al, Incidence of pelvic endometriosis in Rochester, Minnesota[J],1970-1979.Am J Epidemiol, 1987,126:959-969.
[13]Goldstein DP, DeCholnoky C, Emans SJ, et al. Laparoscopy in the diagnosis and management of pelvic Pain in adolescents[J]. J ReProd Med,1980,24:251-256.
[I4]Vessey MP,et al.Epidemiology of endometriosis in women attending family planning clinics[J]. BMJ,1993,306:182.
[15]周应芳.盆腔子宫内膜异位症发病因素的调查[J].中华妇产科杂志,1995,30(6)：356.
[16]潘凌亚.月经状况与子宫内膜异位症发病的关系[J].中华妇产科杂 志,1993,28：147.
[17]罗洁.203例子宫内膜异位症患者月经生殖状况分析[J].云南医药,2000,21(2)：125.
[18]张晓莉.106例子宫内膜异位症病因分析[J].实用医学杂志,1996,12(2)：95.
[19]CoPPeman AB and OliveD. Pathogenesis of pelvic pain in endomet-riosis. In Nezhat CR, et al.Endometriosis:advanced management and surgical techniques[J].NY.SPringer-Verlag,1995,37-43.
[20]Schulman H, et al. The uterine contractility index:a researcher and diagnostic tool in dysmenorrheal [J]. Am J Obstet Gynecol,1983,145:1049.
[21]Wild RA, Wilson EA. Clinical presentation and diagnosis in:Wilson EA Endometriosis[J]. NY. Alan R. Liss. Inc 1987,55-57.
[22]Dmowski WP. The role of medical management in the treatment of endometriosis [J], In:Nezhat CR, et al techniques.NY.Springer-Verlay.1995,229-240.
[23]许卫华,梁雪芳.月经与生殖状况与盆腔子宫内膜异位症关系的探讨[J].广州中医药大学学报,2002,19(1)：12
[24]Vessey MP.Vill ard-Mackintosh L,Painter R, Epidemiology of endometriosis in women attending family planning clinics [J]. BMJ, 1993,306:182-184.
[25]Sangi-Hagheyker H,Poindexter A 3rd.Epidemiology of endometrios is among parlous women[J]. Obstet Gynecol,1995,85 (6):983-992.
[26]王琳.子宫内膜异位症痛经患者腹腔液前列腺素测定28例分析[J].中国实用妇科与产科杂志,1996,12(2)：99.
[27]杨永斯.356例妇女子宫内膜异位症调查[J].广西医学,2002,24(4)：558.
[28]周应芳,王贞娟.子宫腺肌症患者妊娠和计划生育手术史调查[J].北京医学,1996,18(2)：78.
[29]周应芳.盆腔子宫内膜异位症和计划生育手术史的关[J]系.北京医学,1993.15：146.
[30]刘义.不孕妇女子宫内膜异位症发病因素的调查[J],同济医科大学学报,1997,26(1)：73-74.
[31]Makhlouf OC, et al. Endometriosis in lebanon:a Control study[J]. Am J Epidemiol,986;125:762
[32]潘凌亚.子宫内膜异位症发病与个体因素的关系[J].中华医学杂志,1995,75(1)：34.
[33]Parazzini F.Vercellini P.Panazza S,et al. Risk factors for adenomyosis. Hum Reproduce,1997,12:1275.
[34]Cramer DW, Wilson E, Stillman RJ et al. The relation of endometriosis to menstrual characteristics, smoking, andexercise-s.JAMA, 1986,255:1904.
[35]Signorello LB, et al. Epidemi ologic determinants of endometrio-sis: a hospital-based case-control study. Ann Epidemiol,1997,7(4):267.
[36]Berube S, et al. Characteristics related to the prevalence of minimal or mild endometriosis in infertilewomen. Canadian Collaborative Group onEndometriosis. Epidemiology,,1998,9(5):504.
[37]Grodstein F, Goldman MB, Ryan L et al.Relation of female infertility to consumption of caffeinated beverages.Am J Epidemiol,1993,137:1353.
[38]杨银芝译.子宫内膜异位症与机体脂肪分布有关.现代诊断与治疗,1994,5(3)：192.
[39]Signorello LB, et al. Epidemiologic determinates of endometr-iosis: a hospital-based case-control study. Ann E Epidemiol,1997,7(4): 267-741.
[40]Rier SE, Martin DC, Bowman RE, et al. Endometriosis in rhesus monkeys(Macaca mulatta)fol lowing chronic exposure to 2,3,78-tetrach lorodibenzo-P-dioxin. Fundam Appl Toxivol,1993,21(4):433.
[41]郭志荣,张琚,郎景和等.子宫腺肌症患者在位子宫内膜雌激素效应相关因子的时空变化[J].中华妇产科杂志,2004,39(4)：245.
[42]Dickinson CJ.Br J Obstet Gynaecol[M],1999:106:1003-1005.
[43]Hassan HM.Incidence of endometriosis in diagnostic Laparoscopy[J]. Repord Med 1976; 16(3) 135.
[44]纪巍,宋晖.子宫内膜异位症的发病机制研究[J].国外医学妇幼保健分册,2000,11(4)：145-147.
[45]Weed JC, Arquembourg PC. Endometriosis. Can it produce an autoimmune response resulting in infertility Obstet Gynecol[J], 1980,23:885.
[46]唐莉,黄荷凤.子宫内膜异位症的分子遗传学研究进展[J].国外医学妇产科学分册,2006,33(3)：177-283.
[47]Koninekx PR.Brosen IA.Reprod Med,1980,24:257-259.
[48]Kerr JF, Wyllie AH, Currie AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics [J].Br J Cancer.1972,26(4):239-257.
[49]Padykula HA.Regenratin of primate uterus:the role of stem cells.Ann NYA and Sci,2004,622:47-56.
[50]王立杰,郎景和.子宫内膜异位症疾病相关基因的研究[J].现代妇产科进展,2004,13(3)：190-193.
[5]Nisolle M,Casanas-Roux F, Donnez J. Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice. Fertil Steril.2000,74:306-312.
[52]Witz CA,Thomas MR,Montoya-Rodriguez ZA,et al. Short-term culture of peritoneum explants confirm attachment of endometrium to intact peritoneal me sothelium[J]. Fertil Steril.2001,75:385-390.
[53]Koks CA.M, Groothuis PG, Slaats P, Dunsilman GA.J, de Goeij AF.P, and Evers JL.H, Matrix metalloproteinases and their tissue inhibitors in antegradelyshed menstruum and peritoneal fluid[J]. Fertil Sterril, 2000,73:604-612.
[54]Folkman J:The role of angiogenesis in tumor growth [J].Semin Cancer Biol 1992;3:65-71.
[55]彭兆玉主编.子宫内膜异位症/妇产科专题讲座[M]。广东：广东科技出版社,1984,337-347.
[56]陈如钧,江鱼主编。不孕不育治疗学[M]。上海：上海科学技术出版社,1995,93-96.
[57]周应芳,子宫内膜异位症专家座谈会,中国实用妇科与产科杂志,2002,(3)：132.
[58]郎景和,冷金花等。子宫内膜异位症[J],现代妇产科进展,2006,15(3),165-166.
[59]石一复.子宫内膜异位的诊断与治疗现状[J].中华妇产科杂志,1996,31(10)：579-581.
[60]Kennedy S, Bergqvist A, ChaPron C, et al.ESHRE guideline for the diagnosis and treatment of endometriosis[J].Hum Reprod.2005,20: 2698-2704
[61]Aggarwal BB. Nuclear factor-kappa B:the enemy within[J]. Cancer Cell,2004,6:203-208.
[62]Shishodia S, Aggarwal BB. Nuclear factor-kappa B activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer[J].CancerTreat Res,2004,119:139-173.
[63]Grumont RJ, Gerondakis S.Rel induces interferon regulatory factor-4(IRF-4) expression in lymphocytes:modulation of interferon-regulated gene expression by Rel/nuclear factor kappa-B.Exp Med, 2000,1919(8):1281-1292.
[64]ChenF,Castranova V,Shi X, et al. New insights into the role of nuclear factor-kB, a ubiquitous transcription factor in the initiat ion of disease. Clin Chem,1999,45(1):7-17
[65]Raffi G, Raelene G, MathisG,et al. Rel/NF-Kb transcription factors:key mediators of B-cell activation. Immunol Rev,2000,176 (1):134-140.
[66]Neumann M, Naumann M. Beyond IJBs:alternative regulation of NF-kB activity[J].FASEB J Rev,2007,21:2642-2654.
[67]Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer:from innocent bystander to major culprit. Nat Rev,2002,Cancer 2:301-310
[68]Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammati on and cancer. Clin.In vest,2001,107:135-142.
[69]Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart:to be or not to NF-κB [J].Circ Res,2011,108 (9):1122-1132.
[70]Kawamura N, Kubota T, Kawano S, et al. Blockade of NF-κB improves cardiac function and survival without affecting inflamm-ation in TNF-A-induced cardiomyopathy [J]. Cardiovasc Res,2005,66:520-529.
[71]Brown M, Mc Guinness M, Wright T, etal. Cardiac-specific bloc-kade of NF-κB in cardiac pathophysiology:differences between acute and chronic stimuli in vivo[J]. Am J Physiol Heart Circ Physic,1 2005,289:H466-H476.
[72]De Martin R,Hoeth M, Hofe-Warbinek R,et al. The transcription factor NF-kappaB and the regulation of vascular cell fuction[J]. Arterioscler Thromb Vasc Biol 2000,20(11):83-88.
[73]Sasu S, Beasley D. Essential roles of I kappaB kinases alpha and beta in serum and IL-1-induced human VSMC proliferation[J].Am J Phsiol Heart Circ Physiol,2000,278(6):1823-1831.
[74]Chen Y, WU J. Ghosh G.KappaB-Ras binds to the unique insert within the ankyrin repeat domain of I kappaB beta and regulates cytoplasmic retention of I kappaB beta x NF-kappaB complexes[J]. J Biol Chem, 2003,278:23101-23106.
[75]Kanayama A, Seth RB, Sun L, et al.TAB2 and TAB3 Activate the NF-kappaB pathway through binding to polyubiqultin chains [J].Mol Cell,2004,15,535-548.
[76]Wong ET, Tergaonkar V. Roles of NF-kappa B in health and disease: mechanisms and therapeutic potential[J]. Clin Sci (Lond),2009,116(6) 451-465.
[77]Hayden MS, Ghosh S. Signaling to NF-κB [J]. Genes Dev,2004,18: 2195-2224.
[78]Yamamoto Y, Gaynor RB.IkappaB kinases:key regulators of the NF-kappaB pathway[J]. Trends Biochem Sci,2004,29:72-79.
[79]Hayden MS, Ghosh S. Signaling to NF-κB [J]. Genes Dev,2004,18: 2195-2224.
[80]Gilmore TD. Introduction to NF-κB:players, pathways, perspec-tives[J]. Onco-gene,2006,25:6680-6684.
[81]Janssens S, Tschopp J. Signals from within:the DNA-damage-induced NF-κB response[J].Cell Death Differ,2006,13:773-784 (review),21: 2642-2654
[82]Neumann M, Naumann M. Beyond I-κB s:alternative regulation of NF-κB activity [J].FASEB J Rev,2007,21:2642-2654.
[83]Lorenzo O,Picatoste B, Ares-C arrasco S, et al. Potential role of nuclear factor κB in diabetic cardiomyopathy[J].Mediators Inflamm,2011,2011: 652097.
[84]Perkins ND.Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway[J]. Oncogene,2006,25(51) 6717-6730.
[85]中国中西医结合学会妇产科专业委员会第三届学术会议.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准[S].中西医结合杂志,1991,11(6)：376.
[86]高月平.从痰论治子宫内膜异位症.山东中医杂志[J],2000,19(11)：693.
[87]吴凡,祖玉梅.辨证治疗子宫内膜异位症53例[J],辽宁中医杂志,1997,24(3)：122.
[88]马仲平等.韩冰教授辨证治疗子宫内膜异位症经验介绍[J].天津中医,1998,15(4)：230.
[89]吴新华等.康正消异颗粒对120例子宫内膜异位症患者免疫调节作用的影响[J].中医杂志,2003,44(9)：680.
[90]霍清萍.补肾化瘀法治疗子宫内膜异位症32例[J].江苏中医,1998,19(1)：24.
[91]贾美君.补肾疏肝化瘀法治疗子宫内膜异位症60例[J].新中医,2001,33(6)：53.
[92]周惠芳.补肾化瘀法治疗子宫内膜异位症34例[J].吉林中医药,1997,(5)：17.
[93]蔡辉.活血调经方治疗子宫内膜异位症的临床研究[J].中医药学报,199(1)：19.
[94]翟敏.穿蛭合剂治疗子宫内膜异位症48例临床观察[J].河北中医,1999,21(2)：87.
[95]王应兰等.温肾疏化法对子宫内膜异位症患者外周血TNF-α和IL-8的影响[J].山西中医,2002,18(4)：47.
[96]王砚琳.补肾疏肝、痰瘀同治法治疗子宫内膜异位症临床观察[J].山东中医杂志,2002,22(4)：207.
[97]陈建荣.中药综合治疗子宫内膜异位症50例临床观察[J].中国误诊学杂志,2002,2(3)：379.
[98]李友第,等.芪藤汤治疗复发性子宫内膜异位症48例[J].浙江中医杂志,2002：296.
[99]陆涛等.七厘失笑棱莪汤保留灌肠治疗子宫内膜异位症57例[J].上海中医药杂志,1998,(10)：38.
[100]倪建俐等.中药口服与灌肠治疗子宫内膜异位症的疗效对比观察[J].福建中医药,1999,30(4)：5.
[101]郑美华.当归芍药散加减治疗子宫内膜异位症体会[J].新疆中医药,2001,19(4)：19.
[102]吴根土.子宫内膜异位症、子宫腺肌病的中医证型与实时超影像图关系的分析[J].当代医学,2007,127(10)：87-88.
[103]薛江丽.分型论治子宫内膜异位症临床观察[J].山西中医,2013,29(9)：16.
[104]李鹤文.中西医治疗子宫内膜异位症的临床观察[J].四川中医,2013,31(8)：90-91.
[105]中华人民共和国卫生部.《中药新药临床研究指导原则》[M].北京：卫生部出版社,1993：263-265.
[106]赵富爱.辨证分型治疗子宫内膜异位症36例[J].山西中医,2008,24(3)：17-18.
[107]高耀洁,郭竞先.实用中西医结合妇产科学[M].第2版.郑州：河南科技出版社,2000：356.
[108]张丽蓉.求子必读·妇宝良方[M].天津：天津科技翻译出版社,1995：594.
[109]应瑛.化膜汤治疗子宫内膜异位症[J].浙江中医学院学报.1998,22(2)：23-24.
[110]朱振华.加味下瘀血汤治疗子宫内膜异位症42例[J].四川中医,2001,19(5)：49.
[111]钱静.温肾化瘀法治疗子宫内膜异位症的临床观察[J].南京中医药大学学报,2000,16(5)：277.
[112]司徒仪.莪棱胶囊治疗气滞血瘀型子宫内膜异位症临床研究,上海中医药杂志,2008,42(3)：46-48.
[113]蔡嘉兴.散结止痛汤治疗子宫内膜异位症临床研究[J]河北中医2000,2(：)8-9
[114]高琦,蔡霞.祛瘀散结方保留灌肠防治盆腔子宫内膜异位症术后复发疗效观察[J].新疆医科大学学报,2013,36(10)：1470-1472.
[115]周世谊.中药灌肠治疗子宫内膜异位症64例疗效观察[J].中国医药指南,2012,1 0(4)：226-228.
[116]赵月娥,程少华,叶林珍.中医外敷及灌肠治疗复发性子宫内膜移位症及控制内膜移位症复发的临床应用[J].齐齐哈尔医学院学报,2012,33(9)：1190.
[117]侯英慧,陈莹,中西医治疗子宫内膜异位症进展[J],辽宁中医杂志,2005,32(4)：377-378.
[118]张敏.腹舒粘敷贴治疗内脏平滑肌痉挛性疼痛临床疗效综述[J].今日科技,2006,6：44-45.
[119]夏红,江月华.中药敷贴治疗女性下腹痛333例[J].上海铁道大学学报(医学版),1996,10(3)：211-213.
[120]王倩,汪慧敏.麝香贴敷神阙穴治疗重度痛经的临床疗效观察[J].浙江中医学院学报,2004,28(4)：66.
[121]王金权等,女病外治良方妙法[M]第一版中国中医药出版社 1993：390-391.
[122]石燕华.针灸治疗子宫内膜异位症16例[J].上海针灸杂志,1995,14(4)：148-149.
[123]母丽杰,针灸治疗子宫内膜异位症72例疗效观察[J].中国当代医药,2012,19(12)：80-82)
[124]汪慧敏,侯钦銮.针灸治疗子宫内膜异位症46例[J].中医杂志,2001,42(6)：377-378.
[125]苏颖,张丽.治疗子宫内膜异位症经验[J].人泮中,2000,17(2)：2-3.
[126]陈建荣,等.中药综合治疗子宫内膜异位症50例临床观察[J].中国误诊学杂志,2002,2(3)：379.
[127]金季玲.内外合治子宫内膜异位症53例[J].南京中医药大学学报1999,15(6)：381.
[128]陈德甫,吴宁芬,狄文,子宫内膜异位症用雷公藤多试治疗[J],上海中医药杂志,1994,(9)：6.
[129]顾江红,何嘉琳等,雷公藤治疗子宫内膜异位症40例临床观察[J],中国中医药科技,2003,10(5)：301-302.
[130]赵君利,慕成莉.中西医结合治疗子宫内膜异位症痛经75例[J].福建中医药.2002.33(3)：11-12.
[131]朱文新.中西医结合治疗手术后复发内异症31例[J].中国中西医结合杂志.1997,(4)：241.
[132]解月波.中西医结合治疗子宫内膜异位症60例[J].湖南中医杂志.2003,19(2)：45.
[133]陈清郁.卵巢子宫内膜异位囊肿26例临床分析[J].贵阳医学院学报,2002,27(3)：3.
[l]Vernon MW, Wilson EA. Studies on the surgical induction of endometrio-sis in the rats. Fertile Sterile 1985,44(5):684-694.
[2]王群华,凌斌,赵卫东,等.人蜕膜移植建立NOD/SCID鼠子宫内膜异位症模型[J].安徽医科大学学报.2005,40(2)：99-101.
[3]Jones RC. The effect of a luteinizing hormone releasing hormone(LRH) agonist (Wy-40,972),levonorgestrel, danazol and ovariectomy on experimental endometriosis in the rat[J].Acta Endocrinol,1984, 106(2):282-288.
[4]周玲,钱志红,任琼珍.皮下注射子宫内膜法建立Lewis大鼠腹壁子宫内膜异位症模型[J].江苏医药,2012,38(13)：1513-1515.
[5]凌斌,王群华,陈峥峥,等.人免疫功能重建鼠子宫内膜异位症模型及建模方法[P]：[中国 安徽],200510037684.2005-08-03.
[6]Padykula HA.Regenratin of primate uterus:the role of stem cells.Ann NYA and Sci,2004,622:47-56.
[7]Keenan JA, Williams-Boyes PK, Massey PJ, et al. Regression of endometriosis explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril,1999, 72:135-139.
[8]郝光荣.实验动物学[J].上海：第二军医大学出版社,1999,177-178.
[9]Rajkumar K, Schott P W, Simpson C W, et al. The rat as an animal model for endometriosis to examine recurrence of ectopic endometrial tidue after regression. Fertil Steril,1990,53 (5):921.
[10]苗明三主编.实验动物和动物实验技术[M].北京：中国中医药出版社1997,323-324.
[11]杨耀芳,王钦茂,方学明,等.建立大鼠子宫内膜异位症模型的评价方法.中国药理学通报,1998,14(5)：469.
[12]常暖,韩冰,李同玺.大鼠子宫内膜异位症模型的建立及其病理学观察.临床与实验病理学杂志,1998,14：67-69.
[13]郑澄宇,杨冬梓,谢梅青,等.大鼠子宫内膜异位症模型的建立及其组织学观察.中山医科大学学报,2001,22：106-109.
[1]徐叔云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,2002.
[2]方肇勤.分子生物学技术在中医药研究中的应用[M]上海：上海科学技术出版社,2008.
[3]乐杰.妇产科学第七版[M].人民卫生出版社,325.
[4]Hassan HM.Incidence of endometriosis in diagnostic Laparoscopy J Repord Med 1976; 16(3) 135.
[5]Neumann M, Naumann M. Beyond IJBs:alternative regulation of NF-κB activity[J].FASEB J Rev,2007,21:2642-2654.
[6]Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer:from innocent bystander to major culprit. Nat Rev,2002,Cancer 2:301-310.
[7]Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. Clin.Invest.2001,107:135-142.
[8]Gonzalez-Ramos R, Dornnez J, Defrere S, et al.Nuclear factor-kappa B is constitutively activated in peritioneal endometriosis.Mol Hum Reprod,2007,13(7):503-509.